Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering« Back to News
Fourteen new patents expand worldwide protection of the unique beneficial designs of AlivaMab Mouse and AlivaMab antibodies, and Ablexis' innovations in immunoglobulin transgene engineering
SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC, a biopharmaceutical company focused on licensing its transgenic mouse platforms for antibody drug discovery, today announced further expansion of its intellectual property portfolio directed to its AlivaMab Mouse platform and its groundbreaking insights into the design and engineering of well-functioning immunoglobulin transgenes for antibody drug discovery and development. The expanded portfolio includes recently issued United States patents 10,492,476; 10,494,445; 10,526,420; 10,555,506; 10,561,123; 10,575,504; 10,604,587; 10,618,977; 10,626,188; 10,638,736; and 10,662,255; Canadian patent 2,739,038; and Korean patents 10-1987351 and 10-2004106. Among the expanded portfolio are United States patent claims to heavy and light chain immunoglobulin transgenes comprising human V coding sequences under the control of their mouse regulatory elements, as well as mammalian cells and mice comprising such transgenes.
“We are gratified that patent offices around the world are recognizing the foundational innovations of the AlivaMab antibody design and our insights in the design and engineering of well-functioning synthetic chimeric immunoglobulin transgenes,” said Larry Green, Ph.D., Chief Executive Office of Ablexis, LLC. "Companies experienced in the science and business of antibody drug discovery and development increasingly choose the AlivaMab Mouse as the best platform for providing the most efficient and successful path from antibody drug discovery through the clinic."
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. It is the only transgenic animal incorporating fully synthetic, autonomously functioning immunoglobulin transgenes with a curated repertoire of variable gene segments with a unique part-human/part-mouse antibody composition. As a result, the AlivaMab Mouse platform increases efficiencies and reduces risks in antibody drug discovery and development. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including the majority of the top 15 global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at firstname.lastname@example.org.